Effect of statins on kidney disease outcomes: A systematic review and meta-analysis

American Journal of Kidney Diseases

Volumn 67, Issue 6, 2016, Pages 881-892

  Su, Xiaole ^a,b,c,d   Zhang, Lu ^a,b,c,e   Lv, Jicheng ^a,b,c   Wang, Jinwei ^a,b,c   Hou, Wanyin ^a,b,c   Xie, Xinfang ^a,b,c   Zhang, Hong ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Ministry of China   (China)

^c Ministry of Education   (China)

^d SHANXI MEDICAL UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

albuminuria; atorvastatin; cardiovascular events; Chronic kidney disease (CKD); dyslipidemia; estimated glomerular filtration rate (EGFR); hydroxymethylglutaryl CoA reductase inhibitor; kidney disease outcomes; kidney failure; lipid lowering; pravastatin; proteinuria; rosuvastatin; simvastatin; statins; systematic review

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DRUG EFFECT; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84958581286     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.01.016     Document Type: Article

References (99)

1. A.S. Levey, P.E. de Jong, J. Coresh, and et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report Kidney Int 80 1 2011 17 28
2. K. Matsushita, M. van der Velde, B.C. Astor, and et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 9731 2010 2073 2081
3. M. van der Velde, K. Matsushita, J. Coresh, and et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts Kidney Int 79 12 2011 1341 1352
4. R.T. Gansevoort, K. Matsushita, M. van der Velde, and et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts Kidney Int 80 1 2011 93 104
5. B.C. Astor, K. Matsushita, R.T. Gansevoort, and et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts Kidney Int 79 12 2011 1331 1340
6. N.I. Parikh, S.J. Hwang, M.G. Larson, J.B. Meigs, D. Levy, and C.S. Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control Arch Intern Med 166 17 2006 1884 1891
7. B. Bussolati, M.C. Deregibus, V. Fonsato, and et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway J Am Soc Nephrol 16 7 2005 1936 1947
8. C. Guijarro, and J. Egido Transcription factor-kappa B (NF-kappa B) and renal disease Kidney Int 59 2 2001 415 424
9. E.S. Schaeffner, T. Kurth, G.C. Curhan, and et al. Cholesterol and the risk of renal dysfunction in apparently healthy men J Am Soc Nephrol 14 8 2003 2084 2091
10. P. Muntner, J. Coresh, J.C. Smith, J. Eckfeldt, and M.J. Klag Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study Kidney Int 58 1 2000 293 301
11. M. Tonelli, C. Isles, T. Craven, and et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease Circulation 112 2 2005 171 178
12. B. Fellstrom, H. Holdaas, A.G. Jardine, and et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial Kidney Int 66 4 2004 1549 1555
13. J. Huskey, J. Lindenfeld, T. Cook, and et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S) Atherosclerosis 205 1 2009 202 206
14. R. Haynes, D. Lewis, J. Emberson, and et al. Effects of lowering LDL cholesterol on progression of kidney disease J Am Soc Nephrol 25 8 2014 1825 1833
15. J. Kendrick, M.G. Shlipak, G. Targher, T. Cook, J. Lindenfeld, and M. Chonchol Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study Am J Kidney Dis 55 1 2010 42 49
16. M. Rahman, C. Baimbridge, B.R. Davis, and et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Am J Kidney Dis 52 3 2008 412 424
17. S. Sandhu, N. Wiebe, L.F. Fried, and M. Tonelli Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 17 7 2006 2006 2016
18. W. Hou, J. Lv, V. Perkovic, and et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur Heart J 34 24 2013 1807 1817
19. X. Zhang, C. Xiang, Y.H. Zhou, A. Jiang, Y.Y. Qin, and J. He Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials BMC Cardiovasc Disord 14 2014 19
20. C. Baigent, A. Keech, P.M. Kearney, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 2005 1267 1278
21. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement PLoS Med 6 7 2009 e1000097
22. J.P. Higgins, D.G. Altman, P.C. Gotzsche, and et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
23. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
24. M. Roseman, K. Milette, L.A. Bero, and et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments JAMA 305 10 2011 1008 1017
25. C.N. Morris Parametric empirical Bayes inference: theory and applications J Am Stat Assoc 78 381 1983 47 55
26. G. Knapp, and J. Hartung Improved tests for a random effects meta-regression with a single covariate Stat Med 22 17 2003 2693 2710
27. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
28. D.A. Harville Maximum likelihood approaches to variance component estimation and to related problems J Am Stat Assoc 72 358 1977 320 338
29. D.E. Warn, S.G. Thompson, and D.J. Spiegelhalter Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales Stat Med 21 11 2002 1601 1623
30. J.E. Cornell, C.D. Mulrow, R. Localio, and et al. Random-effects meta-analysis of inconsistent effects: a time for change Ann Intern Med 160 4 2014 267 270
31. S.P. Brooks, and A. Gelman General methods for monitoring convergence of iterative simulations J Comput Graph Stat 7 4 1998 434 455
32. S.P. Hozo, B. Djulbegovic, and I. Hozo Estimating the mean and variance from the median, range, and the size of a sample BMC Med Res Methodol 5 2005 13
33. N. Wiebe, B. Vandermeer, R.W. Platt, T.P. Klassen, D. Moher, and N.J. Barrowman A systematic review identifies a lack of standardization in methods for handling missing variance data J Clin Epidemiol 59 4 2006 342 353
34. S.P. Egon The percentage limits for the distribution of range in samples from a normal population (n ≤ 100.) Biometrika 24 3/4 1932 404 417
35. J.J. Deeks, D.G. Altman, and M.J. Bradburn Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis M. Egger, G. Davey Smith, D.G. Altman, Systematic Reviews in Health Care: Metaanalysis in Context 2nd ed. 2001 BMJ Books London 285 312
36. J. Shepherd, J.J. Kastelein, V. Bittner, and et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study Clin J Am Soc Nephrol 2 6 2007 1131 1139
37. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, and et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 5 2009 810 819
38. R.G. Fassett, I.K. Robertson, M.J. Ball, D.P. Geraghty, and J.S. Coombes Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial Atherosclerosis 213 1 2010 218 224
39. D.G. Vidt, P.M. Ridker, J.T. Monyak, M.J. Schreiber, and M.D. Cressman Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) Clin Ther 33 6 2011 717 725
40. A. Sarma, C.P. Cannon, J. de Lemos, and et al. The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome J Am Heart Assoc 3 3 2014 e000784
41. D. Seron, F. Oppenheimer, L.M. Pallardo, and et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial Transplantation 86 1 2008 82 87
42. J. Kjekshus, E. Apetrei, V. Barrios, and et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 22 2007 2248 2261
43. M.E. Thomas, K.P. Harris, C. Ramaswamy, and et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria Kidney Int 44 5 1993 1124 1129
44. S. Nielsen, O. Schmitz, N. Moller, and et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria Diabetologia 36 10 1993 1079 1086
45. G. Tonolo, M. Ciccarese, P. Brizzi, and et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment Diabetes Care 20 12 1997 1891 1895
46. Y. Imai, H. Suzuki, T. Saito, I. Tsuji, K. Abe, and T. Saruta The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group Clin Exp Hypertens 21 8 1999 1345 1355
47. O.A. Gheith, M.A. Sobh, S. Mohamed Kel, and et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome Nephron 91 4 2002 612 619
48. T.M. Lee, M.S. Lin, C.H. Tsai, and N.C. Chang Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers Kidney Int 68 2 2005 779 787
49. T. Nakamura, C. Ushiyama, K. Hirokawa, and et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis Nephrol Dial Transplant 17 5 2002 798 802
50. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 9374 2003 2005 2016
51. S. Bianchi, R. Bigazzi, A. Caiazza, and V.M. Campese A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 3 2003 565 570
52. J. Atthobari, A.H. Brantsma, R.T. Gansevoort, and et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study Nephrol Dial Transplant 21 11 2006 3106 3114
53. V.G. Athyros, D.P. Mikhailidis, A.A. Papageorgiou, and et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study J Clin Pathol 57 7 2004 728 734
54. P.W. Nanayakkara, C. van Guldener, P.M. Ter Wee, and et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study Arch Intern Med 167 12 2007 1262 1270
55. Y. Sawara, T. Takei, K. Uchida, and et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease Intern Med 47 17 2008 1505 1510
56. H. Nakamura, K. Mizuno, Y. Ohashi, T. Yoshida, K. Hirao, and Y. Uchida Pravastatin and cardiovascular risk in moderate chronic kidney disease Atherosclerosis 206 2 2009 512 517
57. M.J. Koren, M.H. Davidson, D.J. Wilson, and et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD Am J Kidney Dis 53 5 2009 741 750
58. R.G. Fassett, J.S. Coombes, D. Packham, K.F. Fairley, and P. Kincaid-Smith Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease Scand J Urol Nephrol 44 1 2010 56 61
59. V.G. Athyros, A. Karagiannis, E.S. Ganotakis, and et al. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study Curr Med Res Opin 27 8 2011 1659 1668
60. M. Abe, N. Maruyama, K. Okada, S. Matsumoto, K. Matsumoto, and M. Soma Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy J Atheroscler Thromb 18 11 2011 1018 1028
61. A. Gupta, C.L. Chang, D. Collier, B. Dahlof, N.R. Poulter, and P.S. Sever The relationship between statin therapy and progression of renal damage among 10305 hypertensive patients randomised in the ASCOT-Lipid-Lowering Arm (LLA) Atherosclerosis 12 suppl 1 2011 158 159
62. A.F. Santos, E. Keitel, A.E. Bittar, and et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study Transplant Proc 33 1-2 2001 1194 1195
63. G. Yasuda, T. Kuji, K. Hasegawa, and et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease Ren Fail 26 4 2004 411 418
64. V. Panichi, S. Paoletti, E. Mantuano, and et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients Nephrol Dial Transplant 21 2 2005 337 344
65. M. Goicoechea, S.G. de Vinuesa, V. Lahera, and et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease J Am Soc Nephrol 17 12 suppl 3 2006 S231 S235
66. I. Holme, R. Fayyad, O. Faergeman, and et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial J Intern Med 267 6 2010 567 575
67. P. Ruggenenti, A. Perna, M. Tonelli, and et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial Clin J Am Soc Nephrol 5 11 2010 1928 1938
68. F. Scanferla, P.P. Toffoletto, D. Roncali, and G. Bazzato Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects Am J Hypertens 4 10, pt 1 1991 868
69. H.J. Milionis, E. Rizos, M. Kostapanos, and et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) Curr Med Res Opin 22 6 2006 1123 1131
70. L.A. Leiter, R.S. Rosenson, E. Stein, and et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study Atherosclerosis 194 2 2007 e154 e164
71. D. Zeeuw, D.A. Anzalone, V.A. Cain, and et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial Lancet Diabetes Endocrinol 3 3 2015 181 190
72. T.M. Lee, S.F. Su, and C.H. Tsai Effect of pravastatin on proteinuria in patients with well-controlled hypertension Hypertension 40 1 2002 67 73
73. K.S. Lam, I.K. Cheng, E.D. Janus, and R.W. Pang Cholesterol-lowering therapy may retard the progression of diabetic nephropathy Diabetologia 38 5 1995 604 609
74. P. Amarenco, A. Callahan, V.M. Campese, and et al. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial Stroke 45 10 2014 2974 2982
75. C.T. Longenecker, C.O. Hileman, N.T. Funderburg, and G.A. McComsey Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial Clin Infect Dis 59 8 2014 1148 1156
76. A. Takazakura, M. Sakurai, Y. Bando, and et al. Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy J Diabetes Investig 6 3 2015 346 353
77. T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, N. Shimada, and H. Koide Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia Am J Nephrol 21 6 2001 449 454
78. T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, and H. Koide Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy Diabetes Care 28 11 2005 2728 2732
79. T. Nakamura, T. Sugaya, Y. Kawagoe, T. Suzuki, T. Inoue, and K. Node Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease Am J Nephrol 26 1 2006 82 86
80. L.F. Fried, K.Y. Forrest, D. Ellis, Y. Chang, N. Silvers, and T.J. Orchard Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes J Diabetes Complications 15 3 2001 113 119
81. E. Dalla Nora, A. Passaro, P.F. Zamboni, F. Calzoni, R. Fellin, and A. Solini Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study J Endocrinol Invest 26 1 2003 73 78
82. Y. Mori, J. Yokoyama, A. Tsuruoka, and Y. Ikeda Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - a randomized control study Jikeikai Med J 39 1992 341 348
83. M. Abe, N. Maruyama, Y. Yoshida, M. Ito, K. Okada, and M. Soma Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease Endocr J 58 8 2011 663 674
84. K. Douglas, P.G. O'Malley, and J.L. Jackson Meta-analysis: the effect of statins on albuminuria Ann Intern Med 145 2 2006 117 124
85. M.A. Blazing, J.A. De Lemos, C.K. Dyke, R.M. Califf, D. Bilheimer, and E. Braunwald The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy Am Heart J 142 2 2001 211 217
86. B. Nazer, K.K. Ray, S.A. Murphy, C.M. Gibson, and C.P. Cannon Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy J Thromb Thrombolysis 36 3 2013 233 239
87. M. Rahman, C.E. Ford, J.A. Cutler, and et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR Clin J Am Soc Nephrol 7 6 2012 989 1002
88. E.A. Stein, D.G. Vidt, J. Shepherd, V.A. Cain, D. Anzalone, and M.D. Cressman Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program Atherosclerosis 221 2 2012 471 477
89. M. Chonchol, T. Cook, J. Kjekshus, T.R. Pedersen, and J. Lindenfeld Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency Am J Kidney Dis 49 3 2007 373 382
90. P.M. Ridker, E. Danielson, F.A. Fonseca, and et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207
91. M. Tonelli, L. Moye, F.M. Sacks, T. Cole, and G.C. Curhan Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease J Am Soc Nephrol 14 6 2003 1605 1613
92. M. Tonelli, P. Jose, G. Curhan, and et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial BMJ 332 7555 2006 1426
93. S.C. Palmer, S.D. Navaneethan, J.C. Craig, and et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Cochrane Database Syst Rev 5 2014 CD007784
94. SHARP Collaborative Group Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease Am Heart J 160 5 2010 785 794
95. M. Manttari, E. Tiula, T. Alikoski, and V. Manninen Effects of hypertension and dyslipidemia on the decline in renal function Hypertension 26 4 1995 670 675
96. Q. Geng, J. Ren, J. Song, S. Li, and H. Chen Meta-analysis of the effect of statins on renal function Am J Cardiol 114 4 2014 562 570
97. M.A. Blazing, R.P. Giugliano, C.P. Cannon, and et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population Am Heart J 168 2 2014 205 212.e201
98. U. Laufs, O.S. Descamps, A.L. Catapano, and C.J. Packard Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention Eur Heart J 35 30 2014 1996 2000
99. V.M. Campese, and J. Park HMG-CoA reductase inhibitors and renal function Clin J Am Soc Nephrol 2 6 2007 1100 1103